Atypical Haemolytic Uraemic Syndrome – RDG

  • Aims of the Group
    • To establish and maintain a registry of all individuals affected by aHUS in the UK
    • To provide information to clinicians on the investigation and management of aHUS
    • To provide information to affected individuals and their families on aHUS
    • To facilitate collaborative research into all aspects of aHUS
  • Current Activities

    In October 2017 a patient focus group was held at the National Renal Complement Therapeutics Centre in Newcastle. aHUS patient representatives from across all of the UK were present to discuss their ideas for generating a National Service for aHUS with patients at its core. To help facilitate discussion staff from the NRCTC, members of the rare disease group and Sandra Currie from Kidney Research UK were present.

    The key wishes from the patient group were:

    1. Patient information- One of our key remits is to provide high quality advice to patients and clinicians about C3G and aHUS. We have developed a website (www.atypicalhus.co.uk) providing both lay and professional advice

    2.  Publicising recent research – an NRCTC Newsletter is now produced on a quarterly basis highlighting recent research, changes to the aHUS service, and a questions to the expert feature. This is available on line (www.atypicalhus.co.uk), by e-mail or by post to all patients, family, friends and clinicians.

    3. Regional patient roadshows. It was suggested that aHUS staff and RDG members could hold patient information meetings around the UK. The first NRCTC regional roadshow was held on the 10th March in Durham with patients attending from the North East and Yorkshire. The next planned event will be in Liverpool.

    4. Patient handheld record – To ensure equality of access, in addition to our digital platforms, we are creating a written version of our aHUS and C3G patient information. This will be included in our aHUS Patient Handheld Record which will be sent to all our patients on initial diagnosis. In addition to providing information this will act as record of important blood monitoring tests and contact information.

  • International Links

    The group has links with members of the International Complement Society, the European Complement Network and the  European Working Party on Complement Genetics in Renal Disease.

  • Patient Support Groups

    The National Renal Complement Therapy Centre‘s website has news and information about aHUS and the NHS specialised service.

  • Reports

    Publications from the aHUS rare disease group

    1.  Walsh PR, Johnson S. 2017 Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child.

     

    1. Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommele A, et al. 2017 Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int.

     

    1. Kerr H, Wong E, Makou E, Yang Y, Marchbank K, Kavanagh D, et al. 2017 Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation. J Biol Chem;292:13345-13360.

     

    1. Hallam D, Collin J, Bojic S, Chichagova V, Buskin A, Xu Y, et al. 2017 An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure. Stem Cells;35:2305-2320.

     

    1. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. 2017 Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int;91:539-551.

    Annual Reports

    aHUS RDG Report 2012

    aHUS RDG Report 2013

    aHUS RDG Report 2015 – 2016

    aHUS RDG Report 2016 – 2017

    aHUS RDG Annual Report 2017-18

  • Group Members
    • Paul Barlow, Professor of Structural Biology, University of Edinburgh
    • Terry Cook, Professor of Renal Pathology, Imperial College
    • Tim Goodship, Professor of Renal Medicine, Newcastle University
    • Claire Harris, Professor, Cardiff University School of Medicine & Head of Complement at GSK, Stevenage, UK
    • Sally Johnson, Consultant Paediatric Nephrologist,  Newcastle Hospitals NHS Foundation Trust
    • David Kavanagh, Senior Lecturer in Nephrology, Newcastle University RDG Lead
    • Kevin Marchbank, Lecturer in Applied Immunobiology, Newcastle University
    • Paul Morgan, Dean of Medicine, Cardiff University School of Medicine
    • Steve Perkins, Professor, Department of Structural and Molecular Biology, University College London
    • Matthew Pickering, Professor of Rheumatology, Imperial College
    • Len Woodward,  aHUSUK Representative
    • Anna Richards, Wellcome Intermediate Clinical Training Fellow, University of Edinburgh
    • Marie Scully, Consultant Haematologist, University College London Hospitals
    • Neil Sheerin, Professor of Nephrology, Newcastle University
    • Paul Warwicker, Consultant Nephrologist, East and North Hertfordshire NHS Trust
    • Aoife Waters, Consultant Paediatric Nephrologist, Great Ormond Street Hospital
  • Disclosure of Conflicts of Interest

    Tim Goodship – Fees received by Newcastle University from Alexion Pharmaceuticals (aHUS Advisory Board, UK CI for eculizumab studies, UK CI for aHUS Registry, lectures and seminars). Chair of the Board of Trustees, Kidney Research UK.

    Claire Harris – Contract of employment as Head of Complement at GSK, Stevenage, UK.

    Matthew Pickering – Fees received from Alexion Pharmaceuticals for invited lectures and funding for pre-clinical studies on experimental complement reagents.

aHUS RDG Version 9 Updated April 2018
Written by the aHUS Rare Disease Group